Total Funding
2
Total FundingVenture - Series Unknown raised
Growth Score
pts
Heat Score
-14 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
3818954
Actimis Pharmaceuticals is a biopharmaceutical company developing small molecule therapeutics for respiratory and inflammatory disorders.
Acquired by 
Boehringer Ingelheim
Taro Inaba: Director
Fred Middleton: Director
About the Company
Actimis Pharmaceuticals, Inc., is a start-up biopharmaceutical company focused on the development of small molecule therapeutics for respiratory and inflammatory disorders. Actimis was created as a spin-off from the respiratory diseases therapeutic research portfolio of Bayer Healthcare AG. The spin-off was founded by Dr. Kevin Bacon and has
received venture financing from a syndicate lead by Sanderling Ventures of San Mateo, California and Mitsui & Co Venture Partners of New York. Dr. Bacon was most recently Vice President and Global Head of Respiratory diseases research at Bayer Yakuhin Ltd., Japan where the programs were initiated.
